top of page

Watch "Palliative Care in Neuroendocrine Cancer">>>

Home
About
Learn
Advocate
Connect
Resources
Reservations
More

Use tab to navigate through the menu items.

G3 Neuroendocrine Neoplasms (NEN) or High Grade

G3 Neuroendocrine Neoplasms (NEN) or High Grade

Grade 3 NET

Alpha PRRT with Pb-212 VMT
CHM-2101 CAR-T cell for GI Cancers
COMPOSE: PRRT with Lu-177 EDOTREOTIDE versus “Standard of Care” in Well-Differentiated Aggressive G2 & G3 GEP-NETS
ComPareNET: Lu-177 DOTATATE vs CAPTEM in Advanced pNETs
IL13Rα2 CAR T Cell Study for Solid Tumor Cancers
Lu-177 + Carboplatin, Etoposide, and Atezolizumab in SCLC
Lu-177 DOTATATE + Olaparib in GEP-NETs SORENTO™: Subcutaneous Octreotide for GEP-NETs (Cam2029)
SWOG S2104: Adjuvant CAPTEM for High Risk pNET

Neuroendocrine Carcinoma (NEC)

Alpha PRRT with Ac-225 + Standard of Care in SSTR+ SCLC
Alpha PRRT with Pb-212 VMT
Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas
DAREON™- 5: DLL-3 BiTE for Neuroendocrine Cancers
DAREON™-9: DLL-3 BiTE + Topotecan in Small Cell Lung Cancer (SCLC)
IL13Rα2 CAR T Cell Study for Solid Tumor Cancers
Lu-177 + Carboplatin, Etoposide, and Atezolizumab in SCLC
Lu-177 DOTATATE + Sunitinib in PNETs
SWOG S2012: Immunotherapy (Atezolizumab) + Standard Platinum
Systemic VSV-IFNβ-NIS and Pembrolizumab in Refractory NSCLC and NEC

LACNETS
PO BOX 370466
DENVER, CO 80237

info@lacnets.org

TERMS & CONDITIONS

© 2024 by LACNETS

bottom of page